Eugene W. Krueger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eugene W. Krueger has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Mark A. McNiven
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905
24 shared publications Shaun G. Weller
21 shared publications- James D. Orth
Department of Systems Biology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA
18 shared publications - Carol A. Casey
VA Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA
2 shared publications - Gina L. Razidlo
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications Hong Cao
Center for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
2 shared publications
Latest Publications
- 6 August 2026
- Published by Wolters Kluwer Health in Hepatology
With no lysine kinase 1 in hepatic stellate cells promotes mouse and human liver fibrosis through glycolytic triosephosphate isomerase 1
Background and Aims: Liver fibrosis and cirrhosis are major global health burdens with limited treatments. Activated HSCs drive fibrosis through increased proliferation, migration, collagen deposition and glycolysis. The aim of this study is to elucidate the signaling events that lead to enhanced glycolysis, subsequent HSC activation, and liver fibrosis. Approach and Results: Utilizing a phospho-kinase array, we identified with no lysine kinase 1 (WNK1) as a new kinase in primary human HSCs activated by the profibrotic PDGF-B. PDGF-mediated glycolysis in HSCs was attenuated by the WNK1 selective inhibitor, WNK-IN-11, as measured by live-cell metabolic assay, Glifon-300 fluorescence, Glucose-Glo assay, and glucose transporter 1 immunofluorescence. To understand how WNK1 promotes glycolysis, we employed chemical genetics where an engineered WNK1 carrying threonine 301 to glycine mutation (WNK1 T301G ) mutant with a modified ATP pocket accommodated a specific ATP-γ-S analogue to thio-phosphorylate its substrates. Thio-phosphorylated proteins were analyzed by mass spectrometry, which identified the glycolytic protein, triosephosphate isomerase 1 (TPI1), as a novel WNK1 direct substrate. TPI1 interacted with WNK1 in condensates, membrane-less phase separation structures. Condensate disruption and knockdown of TPI1 or WNK1 reduced HSC proliferation and migration in vitro. In vivo, pharmacological or genetic WNK1 inhibition significantly attenuated liver fibrosis in carbon tetrachloride and high-fat, choline-deficient, L -amino acid diet mouse models. Finally, WNK1 inhibition reduced fibrogenesis ex vivo in human precision-cut liver slices. Conclusions: These findings identify WNK1 as a previously unrecognized kinase that promotes HSC activation and liver fibrosis via TPI1-mediated glycolysis, highlighting the WNK1-TPI1 axis as a potential therapeutic target.
- 6 August 2026
- Published by Wolters Kluwer Health in Hepatology
With no lysine kinase 1 in hepatic stellate cells promotes mouse and human liver fibrosis through glycolytic triosephosphate isomerase 1
Background and Aims: Liver fibrosis and cirrhosis are major global health burdens with limited treatments. Activated HSCs drive fibrosis through increased proliferation, migration, collagen deposition and glycolysis. The aim of this study is to elucidate the signaling events that lead to enhanced glycolysis, subsequent HSC activation, and liver fibrosis. Approach and Results: Utilizing a phospho-kinase array, we identified with no lysine kinase 1 (WNK1) as a new kinase in primary human HSCs activated by the profibrotic PDGF-B. PDGF-mediated glycolysis in HSCs was attenuated by the WNK1 selective inhibitor, WNK-IN-11, as measured by live-cell metabolic assay, Glifon-300 fluorescence, Glucose-Glo assay, and glucose transporter 1 immunofluorescence. To understand how WNK1 promotes glycolysis, we employed chemical genetics where an engineered WNK1 carrying threonine 301 to glycine mutation (WNK1 T301G ) mutant with a modified ATP pocket accommodated a specific ATP-γ-S analogue to thio-phosphorylate its substrates. Thio-phosphorylated proteins were analyzed by mass spectrometry, which identified the glycolytic protein, triosephosphate isomerase 1 (TPI1), as a novel WNK1 direct substrate. TPI1 interacted with WNK1 in condensates, membrane-less phase separation structures. Condensate disruption and knockdown of TPI1 or WNK1 reduced HSC proliferation and migration in vitro. In vivo, pharmacological or genetic WNK1 inhibition significantly attenuated liver fibrosis in carbon tetrachloride and high-fat, choline-deficient, L -amino acid diet mouse models. Finally, WNK1 inhibition reduced fibrogenesis ex vivo in human precision-cut liver slices. Conclusions: These findings identify WNK1 as a previously unrecognized kinase that promotes HSC activation and liver fibrosis via TPI1-mediated glycolysis, highlighting the WNK1-TPI1 axis as a potential therapeutic target.
- Open Access
- 22 May 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (6)
Secretion of the HBV small surface antigen is driven by an ER autophagic pathway
Chronic hepatitis B (CHB), a major global public health burden, is characterized by the presence of high circulating levels of non-infectious subviral particles (SVPs). These SVPs are mainly composed of small hepatitis B surface antigen (SHBs) and are associated with a dysfunctional HBV-specific immune response. Previous studies exploring the cellular mechanisms and molecular pathways by which SVPs are secreted from hepatocytes have utilized either non-hepatic cells or whole-genome HBV-integrated hepatoma cell lines in which SHBs can also be secreted as a component of the virion envelope. In this study, we provide a detailed examination of SHBs trafficking using biochemical approaches coupled with high-resolution confocal microscopy and live-cell imaging via a novel fluorophore-tagged SHBs probe in both HepG2 and primary human hepatocytes stably expressing SHBs. Our results provide evidence that SHBs utilize a modified ER-Golgi secretory pathway with transit from the ER to the multivesicular body and lysosomal/late endosomal compartments. Importantly, we identified the autophagy adapters ATG5 and LC3B, and the ER-phagy protein atlastin 3 (ATL3), central to mediating SHBs secretion. These findings suggest that SHBs is trafficked through a non-canonical path for secretion and provides new potential therapeutic targets for the treatment of CHB.
- 22 May 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (6)
Open AccessSecretion of the HBV small surface antigen is driven by an ER autophagic pathway
Chronic hepatitis B (CHB), a major global public health burden, is characterized by the presence of high circulating levels of non-infectious subviral particles (SVPs). These SVPs are mainly composed of small hepatitis B surface antigen (SHBs) and are associated with a dysfunctional HBV-specific immune response. Previous studies exploring the cellular mechanisms and molecular pathways by which SVPs are secreted from hepatocytes have utilized either non-hepatic cells or whole-genome HBV-integrated hepatoma cell lines in which SHBs can also be secreted as a component of the virion envelope. In this study, we provide a detailed examination of SHBs trafficking using biochemical approaches coupled with high-resolution confocal microscopy and live-cell imaging via a novel fluorophore-tagged SHBs probe in both HepG2 and primary human hepatocytes stably expressing SHBs. Our results provide evidence that SHBs utilize a modified ER-Golgi secretory pathway with transit from the ER to the multivesicular body and lysosomal/late endosomal compartments. Importantly, we identified the autophagy adapters ATG5 and LC3B, and the ER-phagy protein atlastin 3 (ATL3), central to mediating SHBs secretion. These findings suggest that SHBs is trafficked through a non-canonical path for secretion and provides new potential therapeutic targets for the treatment of CHB.
- Open Access
- 11 October 2025
- Published by MDPI AG in Methods and Protocols
- Vol. 8 (5) , 121
A Practical Guide to Developing and Troubleshooting Patient-Derived “Mini-Gut” Colorectal Organoids for Clinical Research
Patient-derived organoids (PDOs) have emerged as powerful tools in personalized medicine applicable to both non-malignant conditions and to cancer, where they are increasingly used for personalized drug screening and precision treatment strategies in part due to their ability to replicate tumor heterogeneity. They also serve as study model systems to understand disease mechanisms, pathways, and the impact of ex vivo exposures. We present a detailed step-by-step protocol for generating organoids from normal crypts, polyps, and tumors, including methods for tissue processing, crypt isolation, culture establishment, and the transition from basolateral to apical-out polarity for co-culture and exposure-based studies. The protocol also includes immunofluorescence staining procedures for cellular characterization and quality control measures. Our standardized approach successfully generates organoids from diverse colorectal tissues with high efficiency and reproducibility. This comprehensive guide addresses common technical challenges and provides troubleshooting strategies to improve success rates across different sample types. We believe that this resource will enhance reproducibility in organoid research and expand their utility in translational applications, particularly for personalized medicine approaches in colorectal cancer.
- 11 October 2025
- Published by MDPI AG in Methods and Protocols
- Vol. 8 (5) , 121
Open AccessA Practical Guide to Developing and Troubleshooting Patient-Derived “Mini-Gut” Colorectal Organoids for Clinical Research
Patient-derived organoids (PDOs) have emerged as powerful tools in personalized medicine applicable to both non-malignant conditions and to cancer, where they are increasingly used for personalized drug screening and precision treatment strategies in part due to their ability to replicate tumor heterogeneity. They also serve as study model systems to understand disease mechanisms, pathways, and the impact of ex vivo exposures. We present a detailed step-by-step protocol for generating organoids from normal crypts, polyps, and tumors, including methods for tissue processing, crypt isolation, culture establishment, and the transition from basolateral to apical-out polarity for co-culture and exposure-based studies. The protocol also includes immunofluorescence staining procedures for cellular characterization and quality control measures. Our standardized approach successfully generates organoids from diverse colorectal tissues with high efficiency and reproducibility. This comprehensive guide addresses common technical challenges and provides troubleshooting strategies to improve success rates across different sample types. We believe that this resource will enhance reproducibility in organoid research and expand their utility in translational applications, particularly for personalized medicine approaches in colorectal cancer.
- Open Access
- 22 May 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (6)
Ethanol disrupts hepatocellular lipophagy by altering Rab5-centric LD-lysosome trafficking
Background: Previous reports suggest that lipid droplets (LDs) in the hepatocyte can be catabolized by a direct engulfment from nearby endolysosomes (microlipophagy). Further, it is likely that this process is compromised by chronic ethanol (EtOH) exposure leading to hepatic steatosis. This study investigates the hepatocellular machinery supporting microlipophagy and EtOH-induced alterations in this process with a focus on the small, endosome-associated, GTPase Rab5.Methods and Results: Here we report that this small Ras-related GTPase is a resident component of LDs, and its activity is important for hepatocellular LD-lysosome proximity and physical interactions. We find that Rab5 siRNA knockdown causes an accumulation of LDs in hepatocytes by inhibiting lysosome dependent LD catabolism. Importantly, Rab5 appears to support this process by mediating the recruitment of early endosomal and or multivesicular body compartments to the LD surface before lysosome fusion. Interestingly, while wild-type or a constituently active GTPase form (Q79L) of Rab5 supports LD-lysosome transport, this process is markedly reduced in cells expressing a GTPase dead (S34N) Rab5 protein or in hepatocytes exposed to chronic EtOH.Conclusions: These findings support the novel premise of an early endosomal/multivesicular body intermediate compartment on the LD surface that provides a “docking” site for lysosomal trafficking, not unlike the process that occurs during the hepatocellular degradation of endocytosed ligands that is also known to be compromised by EtOH exposure.
- 22 May 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (6)
Open AccessEthanol disrupts hepatocellular lipophagy by altering Rab5-centric LD-lysosome trafficking
Background: Previous reports suggest that lipid droplets (LDs) in the hepatocyte can be catabolized by a direct engulfment from nearby endolysosomes (microlipophagy). Further, it is likely that this process is compromised by chronic ethanol (EtOH) exposure leading to hepatic steatosis. This study investigates the hepatocellular machinery supporting microlipophagy and EtOH-induced alterations in this process with a focus on the small, endosome-associated, GTPase Rab5.Methods and Results: Here we report that this small Ras-related GTPase is a resident component of LDs, and its activity is important for hepatocellular LD-lysosome proximity and physical interactions. We find that Rab5 siRNA knockdown causes an accumulation of LDs in hepatocytes by inhibiting lysosome dependent LD catabolism. Importantly, Rab5 appears to support this process by mediating the recruitment of early endosomal and or multivesicular body compartments to the LD surface before lysosome fusion. Interestingly, while wild-type or a constituently active GTPase form (Q79L) of Rab5 supports LD-lysosome transport, this process is markedly reduced in cells expressing a GTPase dead (S34N) Rab5 protein or in hepatocytes exposed to chronic EtOH.Conclusions: These findings support the novel premise of an early endosomal/multivesicular body intermediate compartment on the LD surface that provides a “docking” site for lysosomal trafficking, not unlike the process that occurs during the hepatocellular degradation of endocytosed ligands that is also known to be compromised by EtOH exposure.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
Supplementary Table 1 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
Supplementary Table 1 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
Supplementary Figure 1 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
Supplementary Figure 1 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
Supplementary Figure 3 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
Supplementary Figure 3 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Video 1 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
Supplementary Video 1 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 1 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
Supplementary Video 1 from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization